Skip to content
2000
Volume 20, Issue 8
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Acromegaly is a rare disease. Improvements in lifespan in these patients have recently been reported due to transsphenoidal surgery (TSS), advances in medical therapy, and strict criteria for defining disease remission. This document reports the opinions of a group of Italian experts who have gathered together their prolonged clinical experience in the diagnostic and therapeutic challenges of acromegaly patients. Both GH and IGF-I (only IGF-I in those treated with Pegvisomant) are needed in the diagnosis and follow-up. Comorbidities (cardio-cerebrovascular disease, sleep apnea, metabolic derangement, neoplasms, and bone/joint disease) should be specifically addressed. Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas.

Loading

Article metrics loading...

/content/journals/emiddt/10.2174/1871530320666200127103320
2020-10-01
2025-05-11
Loading full text...

Full text loading...

/content/journals/emiddt/10.2174/1871530320666200127103320
Loading

  • Article Type:
    Other
Keyword(s): Acromegaly; comorbidities; discrepant; GH; IGF-I; pituitary
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test